

SUPPLEMENTARY DATA

Table 1 of the supplementary data

Medication at discharge by sex

	Total (N = 2043)	Women (n = 483)	Men (n = 1560)
<i>Medication</i>			
Aspirin	2025 (99.1)	478 (99)	1547 (99.2)
P ₂ Y ₁₂ i	2023 (99)	477 (98.8)	1546 (99.1)
Clopidogrel	1173 (58)	45 (72.3)	828 (53.6)
Ticagrelor	707 (34.9)	112 (23.5)	595 (38.5)
Prasugrel	143 (7.6)	20 (4.2)	123 (7.9)
BB	1900 (93)	454 (94)	1446 (92.7)
ACEi/ARB	1481 (72.5)	324 (67.1)	1157 (74.2)
Statins	2016 (98.7)	478 (99)	1538 (98.6)
OAC	168 (8.2)	32 (6.6)	136 (8.7)
AVK	53 (31.5)	11 (34.4)	42 (30.9)
DOAC	115 (68.5)	21 (65.6)	94 (69.1)
MRA	194 (9.5)	42 (8.7)	152 (8)

ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; AVK, antivitamin K; BB, beta-blockers; DOAC, direct oral anticoagulants; MRA, mineralocorticoid receptor antagonists; OAC, oral anticoagulants; P₂Y₁₂i, inhibitors of the P₂Y₁₂ receptor.

The data are expressed as No. (%).

Table 2 of the supplementary data

Death during the first 30 days, during the first year, and at the end of the follow-up and causes of death

	Total (N = 2194)	Women (n = 528)	Men (n = 1666)	P
<i>Deaths < 30 d</i>				
	179 (8.2)	55 (7.4)	124 (1.4)	.03
<i>Deaths during the first year</i>				
	254 (11.6)	75(14.2)	179 (1.7)	.03
<i>Deaths at the end of the follow-up</i>				
	468 (21.3)	140 (26.5)	329 (19.7)	< .001
<i>Causes of death</i>				
Acute MI	213 (45.4)	64 (45.7)	149 (45.3)	
Sudden death	18 (3.8)	6 (4.3)	12 (3.7)	
Heart failure	31 (6.6)	12 (8.6)	19 (5.8)	
Stroke	13 (2.8)	5 (3.6)	8 (2.4)	
Other CV cause	5 (1.1)	1 (.7)	4 (1.2)	
Neoplasia	73 (15.6)	12 (8.6)	61 (18.5)	
Pulmonary	11 (2.4)	4 (2.9)	7 (2.1)	
Infections	41 (8.7)	10 (7.1)	31 (9.4)	
Gastrointestinal	13 (2.8)	6 (4.3)	7 (2.1)	
Accident/trauma	8 (1.7)	3 (2.1)	5 (1.5)	
Other organ failure	7 (1.5)	2 (1.4)	5 (1.5)	
Unknown	15 (3.2)	3 (2.1)	12 (3.7)	
Other non-CV	9 (1.9)	7 (5)	2 (.6)	
COVID-19	12 (2.6)	5 (3.6)	7 (2.1)	

CV, cardiovascular. COVID, coronavirus disease 2019; MI, myocardial infarction. The data are expressed as No. (%).

Table 3 of the supplementary data

Univariate and multivariable Cox regression analysis

	Univariate			Multivariable		
	HR	95%CI	P	HR	95%CI	P
<i>Sex (reference men)</i>	1.44	1.17-1.78	.01	.98	0.76-1.26	.864
<i>Age</i>	1.07	1.06-1.08	< .001	1.07	1.05-1.08	< .001
<i>Hypertension</i>	1.87	1.54-2.28	< .001	1.11	0.87-1.40	.401
<i>Dyslipidemia</i>	1.03	0.84-1.25	.790			
<i>Diabetes</i>	1.93	1.58-2.36	< .001	1.24	0.98-1.58	.075
<i>Smoking</i>	0.52	0.43-0.63	< .001	1.09	0.85-1.40	.481
<i>Chronic kidney disease</i>	3.54	2.71-4.64	< .001	1.52	1.12-2.08	.008
<i>IABP</i>	3.69	2.80-4.85	< .001	0.77	0.52-1.13	.181
<i>Multivessel disease</i>	1.66	1.37-2.06	< .001	1.36	1.09-1.69	.006
<i>Killip Kimball class</i>						
- I						
- II	3.18	2.36-4.27	< .001	1.48	1.06-2.05	.021
- III	4.26	2.76-6.56	< .001	1.50	0.93-2.43	.094
- IV	7.69	6.11-9.68	< .001	4.79	3.39-6.75	< .001
<i>LVEF</i>	0.94	0.93-0.95	< .001	0.98	0.97-0.99	< .001
<i>Previous MI</i>	1.66	1.28-2.15	< .001	0.71	0.44-1.14	.160
<i>Previous PCI</i>	1.40	1.03-1.89	.030	1.18	0.69-2.01	.548
<i>Femoral access</i>	2.50	2.06-3.03	< .001	1.26	1.00-1.60	.052
<i>Failed PCI</i>	2.41	1.61-3.61	< .001	1.13	0.65-1.94	.667
<i>HS-cTnT</i>	1.02	1.02-1.03	< .001	1.01	1.01-1.02	.001
<i>CI-AKI</i>	2.81	2.31-3.41	< .001	1.59	1.26-2.02	< .001

CI-AKI, contrast-induced acute kidney injury; HS-cTnT, high-sensitivity cardiac troponin T; IABP, intra-aortic balloon pump; LVEF, left ventricle ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Figure 1 of the supplementary data. Kaplan-Meier curves showing survival in women and men at the end of the follow-up.

